LLY
Eli Lilly and Company · Healthcare · Drug Manufacturers - General
$1,142.85
-0.61% today · -3.43% 1W
Oct 2 close or latest
PreviewWhy it's moving
Underperforming without a clear catalyst yet
- LLY −0.61% on the last session vs SPY +0.74%: −1.3 pts of stock-specific move.
- 1 analyst action in the past 10 days (1 positive, 0 negative); latest: JP Morgan maintained Overweight, raised target $1,400 → $1,500.
- Market backdrop (Fri): Average Hourly Earnings m/m 0.1% vs 0.3% expected (cooler); Non-Farm Employment Change 29K vs 89K expected (weaker); S&P futures +0.41%, 10-year yield -5bp in the 30 minutes after.
Assembled from Wallsti's own signals.
Meta Analyst score · Buy (+0.85)
Every firm's latest rating in the past year, each weighted by its age (a 3-month-old call counts half as much as today's), blended with the consensus of 30 analysts (+0.93, counted like 1.5 fresh ratings). 20 firms, 13 with a call in the past 3 months.
| Firm | Latest rating | Date | Weight |
|---|---|---|---|
| JP Morgan | Overweight | Sep 28, 2026 | 8% |
| TD Cowen | Buy | Sep 22, 2026 | 8% |
| Guggenheim | Buy | Sep 18, 2026 | 7% |
| HSBC | Reduce | Sep 10, 2026 | 7% |
| Truist Securities | Buy | Aug 7, 2026 | 5% |
| Cantor Fitzgerald | Overweight | Aug 6, 2026 | 5% |
| Wells Fargo | Overweight | Aug 6, 2026 | 5% |
| Citigroup | Buy | Jul 15, 2026 | 4% |
| Bernstein | Outperform | Jul 14, 2026 | 4% |
| UBS | Buy | Jul 13, 2026 | 4% |
| B of A Securities | Buy | Jul 10, 2026 | 4% |
| RBC Capital | Outperform | Jul 8, 2026 | 4% |
Mean target
$1,328.83
+16.3% upside
Median target
$1,385.00
+21.2% upside
Target range
930.00–1,600.00
low to high
Analysts
30
as of Oct 3
Price vs. targets
Low $930
Mean $1,329
High $1,600
Now $1,142.85
Consensus
Strong buy 6Buy 19Hold 3Sell 1Strong sell 1
Rating and target changes
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| Sep 28, 2026 | JP Morgan | Raised target | Overweight | $1,400.00 → $1,500.00 |
| Sep 22, 2026 | TD Cowen | Reiterated | Buy | $1,250.00 |
| Sep 18, 2026 | Guggenheim | Raised target | Buy | $1,273.00 → $1,284.00 |
| Sep 10, 2026 | HSBC | Raised target | Reduce | $850.00 → $940.00 |
| Aug 7, 2026 | Truist Securities | Raised target | Buy | $1,370.00 → $1,376.00 |
| Aug 6, 2026 | Cantor Fitzgerald | Raised target | Overweight | $1,350.00 → $1,410.00 |
| Aug 6, 2026 | Wells Fargo | Raised target | Overweight | $1,280.00 → $1,330.00 |
| Jul 15, 2026 | Citigroup | Raised target | Buy | $1,500.00 → $1,600.00 |
| Jul 14, 2026 | Bernstein | Raised target | Outperform | $1,300.00 → $1,385.00 |
| Jul 13, 2026 | Guggenheim | Lowered target | Buy | $1,235.00 → $1,273.00 |
| Jul 13, 2026 | UBS | Raised target | Buy | $1,250.00 → $1,425.00 |
| Jul 10, 2026 | B of A Securities | Raised target | Buy | $1,251.00 → $1,334.00 |
| Jul 8, 2026 | RBC Capital | Raised target | Outperform | $1,250.00 → $1,500.00 |
| Jul 8, 2026 | Morgan Stanley | Raised target | Overweight | $1,344.00 → $1,347.00 |
| Jul 8, 2026 | Truist Securities | Raised target | Buy | $1,281.00 → $1,370.00 |
| Jul 7, 2026 | JP Morgan | Raised target | Overweight | $1,300.00 → $1,400.00 |
| Jul 6, 2026 | Cantor Fitzgerald | Raised target | Overweight | $1,230.00 → $1,350.00 |
| Jun 25, 2026 | Leerink Partners | Raised target | Outperform | $1,119.00 → $1,232.00 |
| Jun 9, 2026 | Jefferies | Raised target | Buy | $1,330.00 → $1,350.00 |
| May 26, 2026 | B of A Securities | Raised target | Buy | $1,133.00 → $1,251.00 |
| May 5, 2026 | Guggenheim | Reiterated | Buy | $1,183.00 |
| May 5, 2026 | Barclays | Raised target | Overweight | $1,350.00 → $1,400.00 |
| May 4, 2026 | Wolfe Research | Reiterated | Outperform | $1,325.00 |
| May 1, 2026 | Cantor Fitzgerald | Raised target | Overweight | $1,205.00 → $1,230.00 |
| Apr 22, 2026 | Guggenheim | Raised target | Buy | $1,163.00 → $1,183.00 |
| Apr 10, 2026 | Morgan Stanley | Raised target | Overweight | $1,313.00 → $1,327.00 |
| Apr 2, 2026 | B of A Securities | Raised target | Buy | $1,293.00 → $1,294.00 |
| Mar 30, 2026 | Guggenheim | Lowered target | Buy | $1,168.00 → $1,163.00 |
| Mar 17, 2026 | HSBC | Downgrade | Hold → Reduce | $1,070.00 → $850.00 |
| Feb 25, 2026 | RBC Capital | Initiated | Outperform | $1,250.00 |
| Feb 20, 2026 | Barclays | Initiated | Overweight | $1,350.00 |
| Feb 10, 2026 | Freedom Broker | Upgrade | Hold → Buy | $1,050.00 → $1,200.00 |
| Feb 9, 2026 | Deutsche Bank | Raised target | Buy | $1,200.00 → $1,285.00 |
| Feb 5, 2026 | Morgan Stanley | Raised target | Overweight | $1,290.00 → $1,313.00 |
| Feb 5, 2026 | Wells Fargo | Raised target | Overweight | $1,200.00 → $1,280.00 |
| Feb 5, 2026 | Cantor Fitzgerald | Raised target | Overweight | $985.00 → $1,205.00 |
| Feb 5, 2026 | JP Morgan | Raised target | Overweight | $1,150.00 → $1,300.00 |
| Feb 2, 2026 | Freedom Broker | Raised target | Hold | $950.00 → $1,050.00 |
| Jan 20, 2026 | Guggenheim | Lowered target | Buy | $1,163.00 → $1,161.00 |
| Dec 15, 2025 | B of A Securities | Lowered target | Buy | $1,286.00 → $1,268.00 |
Source: Yahoo Finance analyst data, collected daily.